Drugs in Dev. Ophthalmology
Phase II/ Phase III
Switzerland 
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : European Biotech Acquisition Corp
Deal Size : $80.0 million
Deal Type : Merger
Details : The proceeds expected to support advanced clinical pipeline of multiple innovative products, potentially including the first topical eye-drop for OCS-01 (dexamethasone), the first biologic eye-drop for DED and the first neuroprotective agent for neuro-re...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : European Biotech Acquisition Corp
Deal Size : $80.0 million
Deal Type : Merger
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dataset shows that OCS-01 (dexamethasone) eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
